News
Viking Therapeutics' VENTURE-Oral study of VK2735 has completed enrollment, with a readout set for H2'25. Learn why VKTX ...
Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback